Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Theophylline monohydrate, 99%, Thermo Scientific Chemicals
Click to view available options
Quantity:
50 g
250 g
1000 g
Description
Theophylline monohydrate is a methylxanthine drug used in therapy for respiratory diseases such as COPD and asthma
This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
Solubility
Soluble in water (8 g/L at 20°C).
Notes
Keep container tightly sealed. Store in cool, dry conditions in well sealed containers. Incompatible with oxidizing agents.
Soluble in water (8 g/L at 20°C).
Notes
Keep container tightly sealed. Store in cool, dry conditions in well sealed containers. Incompatible with oxidizing agents.
![TRUSTED_SUSTAINABILITY](/content/dam/fishersci/glyphs/Sustain_Badge.png)
Specifications
Melting Point | 270°C to 274°C |
Odor | Odorless |
Quantity | 50 g |
UN Number | UN2811 |
Beilstein | 13463 |
Merck Index | 14,9285 |
Solubility Information | Soluble in water (8g/L at 20°C). |
Formula Weight | 198.18 (180.16 Anhydrous) |
Percent Purity | 99% |
Chemical Name or Material | Theophylline monohydrate |
Safety and Handling
Hazard Category | H301 |
Hazard Statement | GHS H Statement H301 Toxic if swallowed. |
Precautionary Statement | P264b-P270-P301+P310-P330-P501c |
DOTInformation | Transport Hazard Class: 6.1; Packing Group: III; Proper Shipping Name: TOXIC SOLIDS, ORGANIC, N.O.S. |
EINECSNumber | 200-385-7 |
RTECSNumber | XH3850000 |
TSCA | Yes |
Recommended Storage | Ambient temperatures |
RUO – Research Use Only
Provide Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction